Monopar Therapeutics (MNPR) Other financing activities (2021 - 2025)

Monopar Therapeutics has reported Other financing activities for 5 years, with the latest figure at $544800.0 in Q4 2025.

• Quarterly Other financing activities changed N/A year-over-year to $544800.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $565171.0 (up 672722.62% YoY) and the FY2025 annual result came in at $565171.0, up 672722.62% from the prior year.
• Other financing activities improved to $544800.0 in Q4 2025 per MNPR's latest filing, from $214.0 in the prior quarter.
• Over five years, Other financing activities peaked at $1.7 million in Q3 2023 and troughed at -$1.7 million in Q4 2023.
• A 5-year average of $58290.2 and a median of $2462.0 in 2025 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2023 and 2025: Other financing activities jumped 1322305.47% in 2023, then soared 5507.14% in 2025.
• Over 5 years, Other financing activities stood at $17478.0 in 2021, then tumbled by 99.27% to $128.0 in 2022, then tumbled by 1322505.47% to -$1.7 million in 2023, then soared by 100.0% to $84.0 in 2024, then jumped by 648471.43% to $544800.0 in 2025.
• According to Business Quant data, Other financing activities over the past three periods registered $544800.0, $214.0, and $4710.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.